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basis of positron emission tomography (PET) scanning in 
oncological imaging. Glucose and FDG enter the cell via 
the membrane glucose transporter, and phosphorylation at 
position number six prevents glucose and FDG from escap-
ing the cell. Unlike glucose, FDG cannot be catabolised 
in the glycolytic pathway and remains in the form FDG-
6-phosphate for the duration that the molecule remains 
radioactive and visible on PET. The distribution of radiola-
belled FDG reflects the biodistribution of glucose and its 
phosphorylation in the different regions of the body.
In 1931, the German scientist Otto Heinrich Warburg 
showed a relation between the degree of conversion of glu-
cose to lactic acid and tumour growth, and this became the 
basis of cancer imaging with FDG. The Warburg effect is 
a complex of biochemical alterations in the neoplastic cell 
that includes markedly increased aerobic glycolysis in the 
cytosol and impaired mitochondrial oxidative phospho-
rylation. The production of adenosine triphosphate by the 
metabolism of glucose to lactate is caused by up-regulation 
of several enzymes and transporters (glucose transporter 
1, hexokinase II, pyruvate kinase M2, and lactate dehy-
drogenase) [1, 2]. Despite the lower efficiency of energy 
production by aerobic glycolysis than mitochondrial res-
piration, glucose catabolism may generate precursors for 
the synthesis of proteins, nucleic acids, and membranes 
that are essential for cell proliferation. Therefore, the War-
burg effect occurs in cancers and other rapidly proliferat-
ing eukaryotic cells such as yeast cultures and is a universal 
mechanism that may provide growth advantages [3–5].
A small amount of FDG, much lower than obtained 
with pharmacological doses, may cause a concentration 
of radioactivity within a tumour that may be detected eas-
ily with modern PET computed tomography (PET-CT) or 
PET magnetic resonance imaging (PET-MRI) devices. 
The degree of FDG accumulation in healthy tissues may 
Abstract Positron emission tomography, most commonly 
with 18F-fluorodeoxyglucose, is being used for evaluation 
of tumour response to therapy. Limitations of this method 
are associated with (1) fluorodeoxyglucose pharmacoki-
netic properties, (2) the detection system, (3) discrepancies 
between metabolic and anatomic images, and (4) acquisi-
tion standardization. Response to therapy may be evaluated 
with qualitative (Deauville score), semiquantitative (stand-
ardised uptake value), and quantitative methods (Euro-
pean Organization for Research and Treatment of Cancer; 
Positron Emission Tomography Response Criteria in Solid 
Tumours). Methods under evaluation include metabolic 
tumour volume, total lesion glycolysis, and heterogeneity 
of fluorodeoxyglucose uptake. The development of posi-
tron emission tomography scanners that have larger fields 
of view may facilitate tumour assessment based on kinetic 
modelling. Increased clinical use of these methods will 
depend on the development and validation of intuitive and 
simple analytic tools.
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Most malignancies incorporate glucose much more than 
normal tissues. The glucose analogue fluorodeoxyglucose 
(FDG) labelled with the positron emitter fluorine 18 is the 
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enable the identification of pathological areas in most body 
regions, with some restriction for organs that have exclu-
sively glucose-based metabolism such as the brain or that 
participates in FDG excretion such as the kidneys and uri-
nary system.
The most common applications of FDG-PET in oncol-
ogy involve the evaluation of disease extent. For tumours 
that have high accumulation of FDG, most tumours that 
exceed the resolution of the acquisition system are visible 
on PET images except for artefacts. This fact is very impor-
tant for lymph node localisation, and diagnostic accuracy is 
greater for FDG-PET scanning than CT or MRI scanning 
without PET [6, 7].
False negative results with PET scanning may occur 
with tumour pathologies that have low levels of FDG accu-
mulation such as prostate, stomach, or neuroendocrine 
tumours. False negative results also may occur with lesions 
that are below the limits of resolution of the PET scanner 
(currently, 4–5 mm) or lesions that are anatomically close 
to a structure that is moving during the PET examination 
such as the diaphragm. However, false negative results may 
be minimised with careful patient selection and awareness 
of the inherent limitations of the method.
False positive results are currently a greater clinical 
problem than false negative results because many non-neo-
plastic diseases may have a high level of glucose metabo-
lism, such as infections or inflammatory conditions with 
lymph node involvement. In addition, physiological activa-
tion of muscles, bowels, brown fat, and other normal tis-
sues may cause misleading findings on PET scans. How-
ever, false positive results may be minimised with careful 
patient preparation and experience of the nuclear medicine 
specialist.
Imaging with FDG-PET is useful because of the early 
and marked reduction in tumour metabolism in response to 
chemotherapy or radiation therapy. The evaluation of the 
response to therapy involves the comparison of tests before 
and after treatment. The FDG-PET scan may detect a treat-
ment response in a very early phase of treatment, and this 
may enable the identification of chemoresistant tumours 
that may benefit from alternative treatments. In addition, it 
may be important to detect residual disease after treatment 
is completed.
Current PET scans are usually performed with PET-CT 
scanning, but PET-MRI scanners are becoming available. 
The clinical value of PET-CT is well established, but the 
benefits of PET-MRI are being evaluated. The ability to 
detect the photons emitted from the patient is similar, and 
the quality of metabolic imaging is comparable, between 
PET-CT and PET-MRI devices. These methods differ pri-
marily in the morphological method of imaging. The PET-
MRI scan may provide greater inherent contrast to visual-
ise soft tissues, which could be advantageous in evaluating 
pelvic tumours and sarcomas, but PET-CT is better for 
oncological imaging of the lungs. In children, PET-MRI 
is preferred because of the lower radiation dose than with 
PET-CT scanning [8].
Quantification of tumour with positron emission 
tomography
Nuclear medicine techniques including PET scanning have 
limitations that differ from other radiographic studies. 
These limitations are associated with (1) FDG pharmacoki-
netic properties, (2) the detection system, (3) discrepancies 
between metabolic and anatomic images, and (4) acquisi-
tion standardization.
The pharmacokinetic properties of FDG enable a 
dynamic method of image acquisition. The most important 
mathematical model to analyse the dynamic PET data is 
compartmental analysis. The sequential data obtained after 
administration of the radiotracer, (corrected for attenua-
tion, scatter, and radioactive decay) enable determination 
of the concentration of radiotracer in the body region. To 
interpret the PET data, it is assumed that the measured radi-
otracer can be considered in physiologically distinct com-
partments. The most common compartmental model for the 
analysis of PET data is the Patlak plot, a graphical analy-
sis technique that assumes three compartments: the arterial 
blood compartment, the compartment of radiotracer-free 
distribution, and the compartment of specific and irrevers-
ible binding [9]. Quantitative assessment of tumour metab-
olism is performed with pharmacokinetic constants that 
express radiotracer passage between compartments.
Clinical evaluation of dynamic data may be limited 
because of the need to shorten the time of image acquisi-
tion for each patient, the difficulty of arterial blood sam-
pling to evaluate the input function, and the small field of 
view of the PET scanner (approximately 20 cm). In addi-
tion, small differences in time between FDG administra-
tion and PET scanning for different scans (before and after 
treatment) may cause major errors in interpreting radi-
otracer accumulation.
Current PET scanners have a spatial resolution of 
approximately 4 mm. Radiotracer uptake in lesions that 
have diameter <3 times the scanner resolution is affected 
by partial volume effect, which causes loss of apparent 
activity. For example, in a PET scanner that has spatial 
resolution 4 mm, the image of a radioactive phantom with 
6-mm diameter may show a maximum measured 60 % real 
activity concentration [10].
Modern PET-CT devices typically require ≥10 min 
between the initial CT scan and PET image acquisition in 
more distal body parts. Therefore, misalignment is usu-
ally present between metabolic and anatomical images. 
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Furthermore, the acquisition of each PET image requires 
≥90 s, and breathing movements make it impossible to 
quantify accurately the metabolism of lesions near the dia-
phragm. Acquisition techniques such as PET gating for 
breathing may be helpful, but these methods lengthen the 
time of acquisition and data processing and are not used 
frequently in clinical settings [11].
Standardised acquisition protocols of the European Soci-
ety for Therapeutic Radiology and Oncology and European 
Association of Nuclear Medicine include information about 
the calibration of the PET scanner, radiotracer uptake time, 
and approach for definition of regions of interests. These 
protocols are used to derive quantitative parameters from 
calculated values such as standardised uptake value (SUV) 
[12]. In contrast with CT scanning, it is not possible to 
compare quantitative measurements of PET scans per-
formed in different institutions.
Qualitative and visual evaluation methods
Comparative visual assessment of PET images is com-
monly practised and frequently enables reliable judgements 
about decreased tumour metabolism after therapy. The 
correct reconstruction of PET images should be checked 
in advance. The projected data are detected on every pair 
of photons originated from positron annihilation forms. A 
sinogram is a graphic expression of the raw data that ena-
bles detection of abnormalities and verification of consist-
ency between pretreatment and control PET scans [13]. 
However, qualitative assessment is less useful when a 
tumour has partial reduction of metabolism after treatment 
and incomplete normalisation. In these cases, the uptake by 
the tumour may be similar to physiological activity present 
in other regions that have a stable level of metabolism. Ref-
erence organs typically include the liver and mediastinal 
tissues.
Early investigation of malignancy by PET was per-
formed with lymphoma, and the earliest systems to assess 
treatment were proposed for these neoplasms. A variable 
portion of a lymphoma mass consists of malignant cells, 
and many patients have residual masses after completion 
of therapy. Morphological examination is insufficient to 
exclude the presence of disease in residual masses or early 
recurrence in normal sized lymph nodes. In addition, the 
shrinkage of the tumour may occur late after treatment and 
is a not a proper criterion in early evaluation. In contrast, 
the metabolic response may be detected after 1–3 cycles of 
chemotherapy and is correlated with overall and disease-
free survival [14–17].
The Deauville score is a popular method for the eval-
uation of qualitative response to treatment of Hodgkin 
lymphoma. This score is based on a simple classification 
of the degree of pathological FDG uptake at the tumour 
compared with the liver and mediastinum (Table 1) [18]. 
Lesions that have FDG radiotracer uptake ≤ liver (Deau-
ville score 1, 2, or 3) are metabolically negative, and 
lesions that have FDG uptake > liver (Deauville score 
4 or 5) are positive (Table 1) [18]. The Deauville score 
was validated in a multicentre trial with many patients 
[19].
In contrast, PET scanning is unsuitable for assessing 
the activity and extent of tumours that have moderate radi-
otracer accumulation, such as renal clear cell carcinoma, 
primary liver tumours, and adenocarcinoma of the prostate 
[20].
Methods based on the standardised uptake value
The SUV, a semiquantitative indicator of FDG uptake by 
tumours, is the ratio between the concentration of radio-
activity measured in a body part and the hypothetical con-
centration of radioactivity that should be measured with 
a homogeneous distribution of radiotracer in the entire 
body [21]. Activity in a tumour may be expressed as the 
voxel that has maximum SUV in the whole tumour volume 
(SUVmax):
where C is the activity at a pixel within the tissue identified 
by regions of interest, and ID is the injected dose per kilo-
gram of the patient’s body weight (w). The SUVmax may 
be measured quickly and easily and is affected less by the 
partial volume effect than mean tumour SUV (SUVmean) 
(Fig. 1).
When the SUVmax is used to monitor a tumour, the 
change in activity (ΔSUV) from initial (SUVmax1) to later 
scans (SUVmax2) may be calculated as:
In addition, the SUV is normalised to a reference activ-
ity, typically the FDG uptake by the liver.
SUVmax = [C(µCi/mL)/ID(µCi)]/w,
�SUV(%) = 100× ([SUVmax2/SUVmax1]− 1).
Table 1  Deauville scoring system for evaluation of Hodgkin lym-
phoma with 18F-fluorodeoxyglucose positron emission tomography
Adapted from Meignan et al. [11]
Deauville Score Radiotracer uptake
1 No lesion uptake > background
2 Lesion ≤ mediastinum
3 Mediastinum < lesion ≤ liver
4 Lesion moderately > liver
5 Lesion markedly > liver
x New lesion uptake unlikely related to lymphoma
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The reliability of SUVmax measurement is affected 
by many factors including attenuation correction, scatter 
correction, respiratory motion, partial volume effect, and 
tomographic reconstruction. The problem of reliability 
necessitates highly standardised protocols for PET imaging 
to provide the same conditions of acquisition and data pro-
cessing between PET examinations for proper comparisons 
[22].
The first quantitative criteria to monitor tumours were 
proposed by the European Organization for Research and 
Treatment of Cancer (EORTC) in 1999. The EORTC cri-
teria defined tumour response to treatment as changes in 
SUV > 15 % after the first cycle of chemotherapy; changes 
in SUV > 25 % afte >1 cycle of chemotherapy; changes 
in FDG accumulation >20 %; or new foci of pathological 
FDG uptake [23].
The PET response criteria in solid tumours (PERCIST) 
is a more detailed classification and requires a more rigor-
ous standardisation for data acquisition and analysis than 
the EORTC criteria (Table 2) [24]. The PERCIST criteria 
define limits for maximum acceptable glycaemia, injected 
dose, and acquisition timing, and these criteria are suitable 
only for examinations performed with hybrid PET-CT scan-
ners. The tumour activity is quantified by the SUV peak, 
which considers the average concentration of radioactiv-
ity in a spherical area (radius, 1 cm) centred on the most 
active part of the tumour. Differences in SUV peak >30 % 
are important. The PERCIST criteria may be applied only 
to lesions >2 cm to avoid errors caused by the partial vol-
ume effect. In addition, an analysis of the reference uptake 
(hepatic or mediastinal) is required in PERCIST to ensure 
the absence of significant differences in FDG biodistribu-
tion from before to after therapy. Commercial programs 
for the application of PERCIST are available for most PET 
workstations.
Several systems have been proposed to correct for the 
partial volume effect. These techniques are based on image 
deconvolution, model-based reconstructions, or the simul-
taneous assessment of radiographic CT or MR images that 
are properly coregistered with PET. No system completely 
eliminates the partial volume effect, but some are valid for 
improving the precision of SUV measurement in small 
tumours. These models still are being validated and were 
not considered in the definition of the EORTC and PER-
CIST criteria. However, it is important to quantify tumours 




Several methodological errors may confound the quan-
tification of tumour metabolism when using the SUV 
parameter. Therefore, other metabolic indices have been 
proposed that consider the radiotracer uptake in the entire 
tumour mass. Radiographic morphological methods can-
not quantify the number of malignant cells because there 
is structural inhomogeneity in neoplastic tissue. However, 
Fig. 1  Fluorodeoxyglucose positron emission tomography-computed 
tomography (FDG PET-CT) images. This patient had lymph node 
metastatases from a planocellular nasopharyngeal carcinoma of the 
right neck (solid arrow) coexisting with Hodgkin lymphoma at the 
left neck (dotted arrow). a Pretreatment FDG PET-CT scan showed 
pathological FDG uptake at the carcinoma and lymphoma. b The 
FDG PET-CT scan after two cycles of chemotherapy (cisplatin, doxo-
rubicin, and cyclophosphamide) showed a partial metabolic response 
of carcinomatous localisation (maximum standardised uptake value 
[SUVmax], −54 %; total lesion glycolysis, −47 %) and complete 
metabolic regression of lymphomatous localisation (SUVmax, 
−69 %; total lesion glycolysis, −82 %; downshifted from Deauville 
4 to Deauville 2)
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the uptake of FDG is indicative of the presence of viable 
tumour cells. Therefore, PET may be used to estimate the 
volume of biologically active tumour (metabolic tumour 
volume).
The main problem in quantifying metabolic tumour 
volume is the definition of the threshold SUV between the 
viable tumour and background tissue. Tumour contours 
may be defined manually, but manual segmentation is time 
consuming and lacks repeatability. Alternatively, the SUV 
threshold may be calculated as the percent maximal tumour 
uptake of FDG in tissues surrounding the tumour or other 
reference organs such as the liver [29–32]. In addition, 
other systems are available that are not based on the SUV 
threshold and that use complex mathematical models to 
detect the tumour-background interface [33–39]. Very high 
repeatability is feasible with some techniques [4].
Total lesion glycolysis
The calculation of metabolic tumour volume is based on 
the definition of tumour boundaries. Therefore, metabolic 
tumour volume does not indicate possible differences in 
the density of neoplastic cells within the tumour. The total 
lesion glycolysis is the product of the average tumour SUV 
(which is an index of the density of neoplastic cells) and 
metabolic tumour volume. The total lesion glycolysis may 
correlate with overall survival in patients who have lung 
cancer, colon cancer with liver metastasis, and non-Hodg-
kin lymphoma (Fig. 1) [40–43].
Heterogeneity of fluorodeoxyglucose uptake
In addition to the volumetric parameters, additional fea-
tures may be extracted from PET images by computational 
methods such as tumour texture and heterogeneity [44]. 
The heterogeneity of FDG distribution within the tumour 
mass may be a useful index of response to treatment. 
Tumour progression is associated with cell proliferation, 
hypoxia, and necrosis, which may decrease homogeneity 
of FDG distribution in the tumour. Mathematical models 
that measure the level of heterogeneity may be useful in 
selected patients [45, 46].
Conclusions
It is feasible to perform early measurement of the effect of 
therapy on cancer, and functional tomographic techniques 
such as FDG-PET may be useful in addition to morphologi-
cal imaging methods. The accuracy in measuring tumour 
Table 2  Classification systems for positron emission tomography evaluation of response to treatment of solid tumours, adapted from Wahl et al. 
[15]
CMR complete metabolic response, EORTC European Organization for Research and Treatment of Cancer, FDG fluorodeoxyglucose, ND not 
defined, PERCIST positron emission tomography response criteria in solid tumours, PMD progressive metabolic disease, PMR partial metabolic 
response, SMD stable metabolic disease, SUL standardised uptake value for lean body mass, SUV standardised uptake value
Parameter EORTC PERCIST
Lesion measure SUVmax and SUVmean in a manually drawn  
region of interest
SUV peak of the tumour
lesion with greatest uptake (primary or metastatic)
Reproducibility ±25 % liver uptake ±20 % and <0.3 SUL on liver
Timing ND <15 min difference from injection to acquisition 
between scans before and after treatment
Acquisition and calibration ND Same scanner and reconstruction software should be 
used for scans before and after treatment
Proper calibration required
Complete metabolic response (CMR) No pathological FDG uptake foci No FDG uptake foci below mean liver activity
No new foci
Partial metabolic response (PMR) After first chemotherapy cycle: SUV reduction 
15–25 %
After subsequent chemotherapy cycles: SUV  
reduction >25 %
SUL reduction >30 % in target lesion with mini-
mum 0.8 SUL decrease
No increase in SUL or size in non-target lesions
Progressive metabolic disease (PMD) Increase >25 % tumour SUV
or
increase >20 % tumour longest dimension
or
appearance of new lesions
SUL increase >30 % in target lesion (minimum,  
0.8 SUL)
or
visible increase of lesion extent (minimum >75 % 
total lesion glycolysis)
or
appearance of new lesions
Stable metabolic disease (SMD) Increase <25 % or decrease <15 % tumour SUV Not CMR, PMR, or PMD
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response is limited by the difficulty in performing dynamic 
analysis of tumour metabolism after the radiopharmaceuti-
cal agent is given. Tumour activity may be affected by many 
variables about the patient and conditions of data acquisi-
tion. The development of PET scanners that have larger 
fields of view may facilitate tumour assessment based on 
kinetic modelling. In addition, signal degradation because 
of the partial volume effect may limit the evaluation of small 
lesions. Measurement error may be decreased by validating 
correction algorithms and integrating these algorithms with 
response criteria such as EORTC and PERCIST. Models 
that are based on total lesion glycolysis or tumour heteroge-
neity may be useful in selected patients. Increased clinical 
use of these methods will depend on the development and 
validation of intuitive and simple analytic tools.
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